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Background
Adult T-cell leukemia/lymphoma(ATLL) has so far had
a very poor prognosis by chemotherapy. From the long-
term observations of our previous clinical trials (NST-1/
NST-2; allogeneic hematopoietic stem cell transplanta-
tion with reduced-intensity conditioning regimen (RIC)
for ATLL patients), we suspect that RIC strategy might
have a possible curative power for ATLL patients (pts).
Objective
We evaluated the safety and feasibility of allogeneic
hematopoietic stem cell transplantation with RIC from
matched sibling donors (MSD) for ATLL pts using a
conditioning regimen consisting of fludarabine and
busulfan. Low-dose antithymocyte globulin was added in
the 1st study (NST-1), while it was omitted for the 2nd
study (NST-2). We present the results of long-term fol-
low-up of the two trials as well as the longitudinal pat-
terns of changes in HTLV-1 proviral load in survivors.
Patients and methods
Between Apr, 2001 and Feb, 2006, 30 pts ranged from
50 to 67 years of age were enrolled in NST-1(16 pts)
and NST-2 (14 pts). After undergoing the conditioning
regimen, they received G-CSF-mobilized peripheral
blood (PB) stem cells from HLA-matched sibling donors
(MSD). Half of the donors were HTLV-1 carriers. The
primary end points in both studies were achievement of
complete donor chimerism before day 90, and absence
of early transplant-related mortality (TRM) before
day100. The HTLV-1 proviral load was estimated using
PB samples serially after RIC. HTLV-1 proviral DNA
was measured by the quantitative PCR amplification of
HTLV-1 pX DNA. The detection limit of the HTLV-1
proviral load was 0.5 The overall survival (OS) curve
was estimated by the Kaplan–Meier method.
Results
The results have been already published elsewhere (Oka-
mura, Blood, 2005, Tanosaki, BBMT, 2008, Choi, BMT,
2011) . Ten of the29 evaluable patients have survived
for a median of 115 months (range, 85-130 months)
after RIC. All of them maintain their good health (Kar-
nofsky PS score ?90%).The majority of survivors have
developed the graft-versus host disease (GVHD) (10/10
pts for acute GVHD and 9/10 pts for chronic GVHD).
Overall and progression free survival rates at 5 years for
the studies were 36% (95% IC, 21 to 51%) and 31% (95%
IC, 17 to 45%), respectively. Serial changes in the
HTLV-1 proviral load after RIC in the pts are heteroge-
neous but can be roughly classified into 3 patterns. In
the first pattern, seen in 3 pts, the proviral load became
undetectable after RIC and continued to remain so. In
the second pattern, seen in 3 pts who had received RIC
from HTLV-1 negative donors, the proviral load had
become undetectable but returned to detectable levels
thereafter. Lastly, in the third pattern, seen in 4 pts who
had received the grafts from HTLV-1-carrier donors,
the proviral load had remained at the carrier level. All
the 10 survivors continue to show complete donor chi-
mera during the observation period regardless of the
HTLV-1 proviral load level.
Conclusion
The long-trem follow–up in our study indicates not only
that RIC from MSD is a feasible treatment modality for
ATL, but also that one third of the pts may be cured
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with this procedure because all survivors are good for
health. As for post-RIC changes in HTLV-1 proviral
load in long-term survivors it seems heterogenous,
which may be categoryzed into 3 patterns.
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